Brokerages expect that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will announce sales of $10.10 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Adamas Pharmaceuticals’ earnings. The lowest sales estimate is $9.30 million and the highest is $11.00 million. The business is expected to announce its next earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Adamas Pharmaceuticals will report full-year sales of $33.23 million for the current financial year, with estimates ranging from $31.23 million to $36.12 million. For the next financial year, analysts expect that the firm will report sales of $95.31 million per share, with estimates ranging from $75.00 million to $116.70 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($1.26) EPS for the quarter, beating the consensus estimate of ($1.41) by $0.15. Adamas Pharmaceuticals had a negative return on equity of 104.86% and a negative net margin of 1,138.59%. The firm had revenue of $7.57 million during the quarter, compared to analyst estimates of $4.84 million.

ADMS has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on Adamas Pharmaceuticals in a research note on Monday, July 16th. They issued a “buy” rating and a $45.00 target price for the company. Mizuho restated a “buy” rating and issued a $75.00 target price on shares of Adamas Pharmaceuticals in a research note on Friday, August 17th. BidaskClub upgraded Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 9th. Finally, ValuEngine lowered Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $46.33.

In related news, insider Jennifer J. Rhodes sold 1,002 shares of Adamas Pharmaceuticals stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $25.48, for a total value of $25,530.96. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Richard King sold 2,501 shares of Adamas Pharmaceuticals stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $25.48, for a total value of $63,725.48. The disclosure for this sale can be found here. 24.60% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the stock. Metropolitan Life Insurance Co. NY boosted its holdings in Adamas Pharmaceuticals by 43.2% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 7,606 shares of the specialty pharmaceutical company’s stock worth $196,000 after buying an additional 2,293 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Adamas Pharmaceuticals by 20.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 13,573 shares of the specialty pharmaceutical company’s stock worth $324,000 after buying an additional 2,322 shares during the last quarter. Allianz Asset Management GmbH boosted its holdings in Adamas Pharmaceuticals by 4.7% in the 1st quarter. Allianz Asset Management GmbH now owns 55,594 shares of the specialty pharmaceutical company’s stock worth $1,329,000 after buying an additional 2,513 shares during the last quarter. Sei Investments Co. boosted its holdings in Adamas Pharmaceuticals by 49.8% in the 1st quarter. Sei Investments Co. now owns 7,627 shares of the specialty pharmaceutical company’s stock worth $182,000 after buying an additional 2,536 shares during the last quarter. Finally, California State Teachers Retirement System boosted its holdings in Adamas Pharmaceuticals by 11.2% in the 1st quarter. California State Teachers Retirement System now owns 26,179 shares of the specialty pharmaceutical company’s stock worth $626,000 after buying an additional 2,645 shares during the last quarter. Institutional investors own 95.51% of the company’s stock.

ADMS stock traded up $0.38 during midday trading on Wednesday, reaching $22.83. The stock had a trading volume of 264,051 shares, compared to its average volume of 427,226. The firm has a market capitalization of $610.43 million, a price-to-earnings ratio of -5.75 and a beta of 1.37. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.92 and a quick ratio of 9.74. Adamas Pharmaceuticals has a 52-week low of $17.68 and a 52-week high of $44.00.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Read More: Moving Average (MA)

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.